The efficacy and tolerance of adjuvant chemoradiotherapy in gastric cancer - A preliminary report;Tolerancja oraz skuteczność uzupełniaja̧cej chemioradioterapii w raku żoła̧dka - Doniesienie wstȩpne

Nowotwory

Volumn 58, Issue 5, 2008, Pages 413-417

  Ochenduszko, Sebastian ^a   Chłosta, Monika ^a   Pawlȩga, Janusz ^a  

^a UNIVERSITY HOSPITAL IN KRAKOW   (Poland)

Author keywords

Chemoradiotherapy; Efficacy; Gastric cancer; Toxicity

Indexed keywords

FLUOROURACIL; FOLINIC ACID;

ABDOMINAL PAIN; ADULT; ARTICLE; CANCER ADJUVANT THERAPY; CANCER RADIOTHERAPY; CANCER STAGING; CLINICAL ARTICLE; DRUG DOSE REDUCTION; DRUG WITHDRAWAL; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; HUMAN; LIVER TOXICITY; MALE; METASTASIS; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; NAUSEA AND VOMITING; POSTOPERATIVE CARE; RADIATION DOSE; STOMACH ADENOCARCINOMA; SURVIVAL RATE;

EID: 58049199377     PISSN: 0029540X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (13)

1. Kamangar F, Dores GM, Anderson WF. Patterns of cancer incidence, mortality, and prevalence across five continents: defining priorities to reduce cancer disparities in different geographic regions or the world. J Clin Oncol 2006; 24: 2137-50.
2. Gunderson LL, Sosin H. Adenocarcinoma of the stomach: areas of failure in a re-operation series (second or symptomatic look) clinicopathologic correlation and implications for adjuvant therapy. Int J Radiat Oncol Biol Phys 1982; 8: 1-11.
3. Landry J, Tepper JE, Wood WC i wsp. Patterns of failure following curative resection of gastric carcinoma. Int J Radiat Oncol Biol Phys 1990; 19: 1357-62.
4. Macdonald JS, Smalley SR, Benedetti J i wsp. Chemioradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction. N Eng J Med 2001; 345: 725-30.
5. Cunningham D, Allum WH, Stenning SP i wsp. Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. N Eng J Med 2006; 355: 11-20.
6. Hartgrink HH, van de Velde CJH, Putter H i wsp. Extended lymph node dissection for gastric cancer: Who may benefit? Final results of the randomised Dutch Gastric Cancer Group trial. J Clin Oncol 2004; 22: 2069-77.
7. Bonenkamp JJ, Songun I, Hermans J i wsp. Randomised comparison of morbidity after D1 and D2 dissection for gastric cancer in 996 Dutch patients. Lancet 1995; 345: 745-8.
8. Cuschieri A, Weeden S, Fielding J i wsp. Patient survival after D1 and D2 resections for gastric cancer: long-term results of the MRC randomized surgical trial. Br J Cancer 1999; 79: 1522-30.
9. van de Velde CJH, Peeters KCMJ. The gastric cancer treatment controversy. J Clin Oncol 2003; 21: 2234-6.
10. van Krieken JH, Sasako M, van de vele CJ. Gastric cancer. W: Gospodarowicz MK, Henson DE, Hutter RVP, O'Sullivan B, Sobin LH, Wittekind C, eds. Prognostic Factors in Cancer. New York: Wiley-Liss. 2001; 251-65.
11. Phase III Randomized Study of Preoperative Versus Postoperative Chemotherapy With Docetaxel, Cisplatin, and Fluorouracil in Patients With Locally Advanced Operable Gastric Carcinoma. http://www.nci.nih.gov/search/View- ClinicalTrials.aspx?cdrid=67658&version=HealthProfessional& protocolsearchid=1145216.
12. Boige V, Pignon J, Saint-Aubert B, i wsp. Final results of a randomized trial comparing preoperative 5-fluorouracil (F)/cisplatin (P) to surgery alone in adenocarcinoma of stomach and lower esophagus (ASLE): FNLCC ACCORD07-FFCD 9703 trial. Proc Am Soc Clin Oncol Jun 1-5 2007: 4510.
13. Lorenzen S, Weigert N, Heinemann V i wsp. Docetaxel, cisplatin and leucovorin/fluororuracil in first-line advanced gastric cancer and adenocarcinoma of the esophagogastric junction: Results of the phase II GASTRO-TAX-1 trial. Proc Am Soc Clin Oncol Jun 1-5 2007: 4561.